Last reviewed 2026-05-29 · How we verify

Diatox (DIATHYMOSULFONE)

Phase 2 active Small molecule ✓ Verified May 2026

Diatox (generic name: DIATHYMOSULFONE) is a diathymosulfone drug. It is currently in Phase 2 development.

Diatox is a small molecule that works by interacting with a specific biological target, although its exact mechanism of action is currently unknown.

Diatox is a small molecule modality. It is also known by the synonyms Diathymosulfone, Diathymosulphone, and Diatimosulfona.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIATHYMOSULFONE
Drug class	diathymosulfone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine Diatox as a key that fits into a lock in the body. When it binds to its target, it can either turn the lock on or off, depending on the desired effect. However, without more information, it's difficult to say exactly how Diatox works or what it does.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diatox CI brief — competitive landscape report
Diatox updates RSS · CI watch RSS

Frequently asked questions about Diatox

What is Diatox?

Diatox (DIATHYMOSULFONE) is a diathymosulfone drug.

How does Diatox work?

Diatox is a small molecule that works by interacting with a specific biological target, although its exact mechanism of action is currently unknown.

What is the generic name of Diatox?

DIATHYMOSULFONE is the generic (nonproprietary) name of Diatox.

What drug class is Diatox in?

Diatox belongs to the diathymosulfone class. See all diathymosulfone drugs at /class/diathymosulfone.

What development phase is Diatox in?

Diatox is in Phase 2.

Drug class: All diathymosulfone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing